A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
OncoResponse, Inc.
Philogen S.p.A.
ChineseAMS
Maria Sklodowska-Curie National Research Institute of Oncology
N.N. Petrov National Medical Research Center of Oncology
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
National Cancer Institute (NCI)